← All trials
NCT03249480
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2015
- Primary completion
- Aug 31, 2017
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 900
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- GeneScience Pharmaceuticals Co., Ltd.Lead sponsor
- Peking UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Hebei UniversityCollaborator
- Kunming Medical UniversityCollaborator
- Soochow UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Shenzhen UniversityCollaborator
- University of South ChinaCollaborator
- Dalian Medical UniversityCollaborator
- Capital Medical UniversityOverall official - principal investigator
- Capital Medical UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- The First People's Hospital of Yunan ProvinceCollaborator
- Zhengzhou UniversityCollaborator
- Fuzhou Children s HospitalCollaborator
- Henan Provincal People's HospitalCollaborator
- Guangxi Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Wuhan Children's HospitalCollaborator
- Wuxi Children's HospitalCollaborator
- Xian Children's HospitalCollaborator
- Xuzhou Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.